Compare THM & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | DRUG |
|---|---|---|
| Founded | 1978 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.5M | 707.1M |
| IPO Year | 2002 | 2020 |
| Metric | THM | DRUG |
|---|---|---|
| Price | $2.47 | $83.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | ★ 1.1M | 179.0K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $244.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $23.18 |
| 52 Week High | $3.65 | $123.75 |
| Indicator | THM | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 51.31 |
| Support Level | $2.21 | $79.55 |
| Resistance Level | $2.84 | $84.29 |
| Average True Range (ATR) | 0.17 | 5.00 |
| MACD | -0.02 | -0.78 |
| Stochastic Oscillator | 34.37 | 63.97 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.